Skip to main content
JIANGSU COWIN BIOTECH CO., LTD. logo

JIANGSU COWIN BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 688426 ISIN · CNE100005NM2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688426

About JIANGSU COWIN BIOTECH CO., LTD.

https://www.cwbiosciences.com/

Jiangsu Cowin Biotech Co., Ltd. specializes in the development and manufacture of molecular biology reagents and kits. The company provides a comprehensive range of products including DNA and RNA extraction and purification systems, PCR and qPCR reagents, protein markers, and antibodies. Additionally, it offers solutions for next-generation sequencing (NGS) library preparation and various laboratory consumables. Serving life science research, clinical diagnostics, and pharmaceutical sectors, the company focuses on delivering reliable tools for genomic and proteomic analysis. Its portfolio supports diverse applications ranging from basic academic research to industrial biotechnology and molecular diagnostics.

Recent filings

Filing Released Lang Actions
关于自愿披露六项呼吸道病原体核酸检测试剂盒（荧光PCR法）获得三类医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of a medical device registration certificate obtained for a specific product. It details the product information, registration details, and potential impact on the company. The document is short (1470 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an official announcement about a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-08 Chinese
2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled "2025年年度股东会会议资料" which translates to "2025 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda, meeting notices, and multiple proposals (议案) to be discussed and voted on at the 2025 AGM. The content includes the board work report, financial reports, annual report proposals, profit distribution plans, auditor appointments, and amendments to governance and remuneration policies. The document is clearly a set of materials prepared for the Annual General Meeting, intended for shareholders to review before or during the meeting. It is not the annual report itself, nor is it a brief announcement or a transcript. The length (over 11,000 characters) and detailed content confirm it is the meeting materials. Therefore, the document fits the category AGM Information (AGM-R).
2026-05-08 Chinese
关于部分董事、高级管理人员减持期限届满未减持股份的结果公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the results of a planned share reduction (share sales) by certain directors and senior management personnel. It details the shareholding before and after the planned reduction period, confirms that no shares were actually sold, and states compliance with relevant laws and regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal disclosure of insider shareholding transactions (or lack thereof) by company directors and executives. This fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3124 characters, which is typical for such announcements. Therefore, the correct classification is DIRS (Director's Dealing).
2026-05-06 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, structure, and mechanisms for determining and managing the compensation of the company's board members and senior executives. The content includes salary composition, performance evaluation, payment mechanisms, and adjustment criteria. There is no indication that this is an announcement or a brief summary; rather, it is a detailed policy document on remuneration. This matches the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document length is about 3007 characters, which is sufficient for a detailed remuneration policy but not a full annual or interim report. Therefore, the appropriate classification is DEF 14A with high confidence.
2026-04-23 Chinese
董事会审计委员会对会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm for the company's 2025 annual audit. It discusses the qualifications of the accounting firm, the audit process, and the committee's oversight activities. The document references the 2025 annual financial audit and internal control audit, and mentions approval of related reports and proposals. The content is focused on the audit committee's evaluation and oversight of the audit firm rather than the full annual report itself. The document length is 1404 characters, which is relatively short and more consistent with a standalone audit-related report rather than a full annual report. Therefore, this document fits best under the category of Audit Report / Information (AR), as it is a standalone report on audit supervision and related audit matters, not the full annual report (10-K) or an announcement of a report (RPA). FY 2025
2026-04-23 Chinese
2026年度“提质增效重回报”行动方案
Annual Report Classification · 95% confidence The document is a detailed annual action plan and performance report for the year 2025 by 江苏康为世纪生物科技股份有限公司, including comprehensive information on business operations, R&D, financial performance, governance, investor relations, and future plans. It contains actual financial figures such as revenue, profit, R&D expenses, and detailed operational data. The document is lengthy (8927 characters) and provides substantive financial and operational analysis rather than just announcing or summarizing a report. It is not a short announcement or a certification letter. The content aligns with a comprehensive annual report covering company activity and full financial performance for the fiscal year 2025. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.